Home  >  News
Msc_Apr22 Advertisement
you can get e-magazine links on WhatsApp. Click here
International + Font Resize -

OvaScience introduces AUGMENT fertility treatment in Japan

Waltham, Massachusetts
Wednesday, December 16, 2015, 17:00 Hrs  [IST]

OvaScienceSM, a global fertility company, announced the AUGMENT fertility treatment is being offered in Japan through a preceptorship programme at IVF JAPAN, one of the most prestigious fertility clinic systems in Japan. The initiation of the preceptorship programme, in which patients will receive the AUGMENT treatment, follows approval from the Japan Society of Obstetrics and Gynaecology (JSOG).

“The introduction of the AUGMENT treatment in Japan represents an important milestone for patients,” said Michelle Dipp, M.D., Ph.D., chief executive officer of OvaScience.

“We look forward to working to expand the availability of the AUGMENT treatment to women who experience poor egg health and are in need of new fertility treatment options.”

Under the leadership of Professor Yoshiharu Morimoto, M.D., Ph.D., IVF JAPAN conducts a combined 10,000 in vitro fertilization (IVF) cycles annually at its three clinics. Professor Morimoto is the president of the Pacific Society of Reproductive Medicine, the past president of the Asia Pacific Initiative on Reproduction, the President of the Japan Society of Assisted Reproduction and the President of the Japan Society of Reproductive Psychology. Japan is the world’s largest IVF market, accounting for more than 326,000 IVF cycles annually.

IVF JAPAN is the first clinic network to offer the AUGMENT treatment in the region. The treatment is being offered through a preceptorship programme, designed for the clinic to obtain patient experience and training before offering the treatment more broadly.

“Bringing forward innovative technologies on behalf of our patients is part of our mission at IVF JAPAN,” said Professor Morimoto, chief executive officer of IVF JAPAN. “We are encouraged by the patient experiences with the AUGMENT treatment published to date, and look forward to seeing how it may improve the chance of success for women who are experiencing poor egg and embryo quality in our clinic.”

The AUGMENT treatment is not available in the United States.

The AUGMENT treatment is the first fertility treatment available to patients based on OvaScience’s proprietary egg precursor (EggPCSM) cell technology. The AUGMENT treatment is designed to improve the health of a woman’s existing eggs and enhance the IVF procedure. The AUGMENT treatment uses energy-producing mitochondria from a woman’s own EggPC cells, which are immature egg cells found in the protective lining of the ovaries, to supplement the existing mitochondria in her eggs. This treatment is designed to improve egg health by increasing the eggs’ energy levels for embryo development. Egg health is a key factor in IVF success. The AUGMENT treatment is available in select international IVF clinics, and positive clinical experiences of pregnancies and births with the treatment have been reported. The AUGMENT treatment is not available in the United States.


* Name :     
* Email :    
  Website :  
Copyright © 2016 Saffron Media Pvt. Ltd |